Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome

[1]  P. Queirolo,et al.  Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity , 2009, Proceedings of the National Academy of Sciences.

[2]  H. Ljunggren,et al.  Down-regulating Dnam-1 on Nk Cells Cd155 Impair Tumor Targeting by Primary Human Tumor Cells Expressing , 2022 .

[3]  K. Kojima,et al.  NKG2D‐mediated immunity underlying paroxysmal nocturnal haemoglobinuria and related bone marrow failure syndromes , 2009, British journal of haematology.

[4]  A. Daneri-Navarro,et al.  Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions , 2009, BMC Cancer.

[5]  G. Ossenkoppele,et al.  Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome , 2009, Haematologica.

[6]  L. Isola,et al.  The evolution of hematopoietic SCT in myelodysplastic syndrome , 2009, Bone Marrow Transplantation.

[7]  H. Ljunggren,et al.  Natural killer cell‐mediated lysis of freshly isolated human tumor cells , 2009, International journal of cancer.

[8]  J. D. Di Santo,et al.  IL-15 trans-presentation promotes human NK cell development and differentiation in vivo , 2009, The Journal of experimental medicine.

[9]  T. Yasui,et al.  Accelerated tumor growth in mice deficient in DNAM-1 receptor , 2008, The Journal of experimental medicine.

[10]  Eric O Long,et al.  Line of attack: NK cell specificity and integration of signals. , 2008, Current opinion in immunology.

[11]  N. Greenberg,et al.  NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. , 2008, Immunity.

[12]  J. Bourhis,et al.  Activation of cytotoxic T-cell receptor γδ T lymphocytes in response to specific stimulation in myelodysplastic syndromes , 2008, Haematologica.

[13]  Alois Gratwohl,et al.  NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. , 2008, Blood.

[14]  T. Haferlach,et al.  A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. , 2007, Haematologica.

[15]  B. Zhong,et al.  Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. , 2007, Blood.

[16]  A. Thiel,et al.  CD56brightCD16− Killer Ig-Like Receptor− NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation1 , 2007, The Journal of Immunology.

[17]  G. Konjević,et al.  Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients , 2007, Clinical & Experimental Metastasis.

[18]  S. Chisholm,et al.  Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Bourhis,et al.  Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes , 2006, Leukemia.

[20]  P. Guldberg,et al.  Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early‐stage patients , 2006, European journal of haematology.

[21]  C. Kalberer,et al.  Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice , 2005, Leukemia.

[22]  D. F. Barber,et al.  Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells , 2005, The Journal of experimental medicine.

[23]  J. Zimmer,et al.  Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells. , 2005, Blood.

[24]  A. Hayday,et al.  Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance , 2005, Nature Immunology.

[25]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[26]  L. Rimsza,et al.  Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.

[27]  R. Biassoni,et al.  Transforming growth factor β1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Steensma,et al.  The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. , 2003, Leukemia research.

[29]  G. Saberwal,et al.  Biological Significance of Proliferation, Apoptosis, Cytokines, and Monocyte/Macrophage Cells in Bone Marrow Biopsies of 145 Patients With Myelodysplastic Syndrome , 2002, International journal of hematology.

[30]  Katia Perruccio,et al.  Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.

[31]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[32]  M. Caligiuri,et al.  The biology of human natural killer-cell subsets. , 2001, Trends in immunology.

[33]  R. Jacobs,et al.  CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells , 2001, European journal of immunology.

[34]  M. Caligiuri,et al.  Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset , 2001 .

[35]  N. Takahashi,et al.  Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence‐activated cell sorting , 2000, British journal of haematology.

[36]  H. Kawasaki,et al.  Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. , 1996, Leukemia.

[37]  H. Heimpel,et al.  NATURAL KILLER CELL ACTIVITY IN PRELEUKAEMIA , 1982, The Lancet.

[38]  K. Rezvani,et al.  The role of the immune system in myelodysplasia: implications for therapy. , 2008, Seminars in hematology.

[39]  Daniel Olive,et al.  Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. , 2007, Blood.

[40]  Eric O Long,et al.  Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. , 2006, Blood.

[41]  J. Bluestone,et al.  Impairment of NK cell function by NKG2D modulation in NOD mice. , 2003, Immunity.

[42]  T. Ghayur,et al.  Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. , 2001, Blood.

[43]  P. Hokland,et al.  Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. , 1984, Leukemia research.

[44]  H. Heimpel,et al.  NATURAL-KILLER CELL-ACTIVITY IN PRE-LEUKEMIA , 1982 .